MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) from its SEC filings: 2025 revenue $185.7 million (-28% vs the year before), net margin -70%, free cash flow -$70.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $185.7 million |
| Revenue growth | -28% |
| Net income | -$130.8 million |
| Net margin | -70.4% |
| Free cash flow | -$70.7 million |
| Diluted EPS | $-0.90 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +8% |
| Cash | $70.1 million |
| Long-term debt | $146.0 million |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.